Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Claire E. Dearden, Amit Khot, Monica Else, Mike Hamblin, Effie Grand, Ashok Roy, Saman Hewamana, Estella Matutes, Daniel Catovsky

Blood (2011) 118 (22): 5799–5802.

https://doi.org/10.1182/blood-2011-08-372854

Published: 2011

Journal Articles

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis

Thet Thet Lin, Boitelo T. Letsolo, Rhiannon E. Jones, Jan Rowson, Guy Pratt, Saman Hewamana, Chris Fegan, Chris Pepper, Duncan M. Baird

Blood (2010) 116 (11): 1899–1907.

https://doi.org/10.1182/blood-2010-02-272104

Published: 2010

Includes: Supplemental data

Journal Articles

L-Gossypol Inhibits NF- κB, Down Regulates Mcl-1 and Induces Apoptosis of Primary Acute Myeloid Leukaemia Cells.

Chris J Pepper, Hani Y Osman, Saman Hewamana, Elisabeth J Walsby, Alan K Burnett, Steven Knapper

Blood (2009) 114 (22): 4813.

https://doi.org/10.1182/blood.V114.22.4813.4813

Published: 2009

Journal Articles

Rel a Is a Novel Prognostic Marker in CLL That Is Independent of V H Gene Mutation Status, CD38 Expression and ZAP-70 Expression

Saman Hewamana, Thet Thet Lin, Clare Rowntree, Kamaraj Karunanithi, Alan Burnett, Paul Brennan, Chris Fegan, Chris Pepper

Blood (2008) 112 (11): 4153.

https://doi.org/10.1182/blood.V112.11.4153.4153

Published: 2008

Journal Articles

Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells

Saman Hewamana, Thet Thet Lin, Chris Fegan, Steven Knapper, Alan Burnett, Paul Brennan, Clare Rowntree, Chris Pepper

Blood (2008) 112 (11): 380.

https://doi.org/10.1182/blood.V112.11.380.380

Published: 2008

Journal Articles

The Parthenolide Derivative LC-1 Is An Effective Single Agent and Is Highly Synergistic with Existing Therapies in Multiple Myeloma.

Elisabeth J Walsby, Saman Hewamana, Alan Burnett, Steven Knapper, Chris Fegan, Chris Pepper

Blood (2008) 112 (11): 1708.

https://doi.org/10.1182/blood.V112.11.1708.1708

Published: 2008

Journal Articles

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

Chris Pepper, Thet Thet Lin, Guy Pratt, Saman Hewamana, Paul Brennan, Louise Hiller, Robert Hills, Rachel Ward, Jane Starczynski, Belinda Austen, Laura Hooper, Tatjana Stankovic, Chris Fegan

Blood (2008) 112 (9): 3807–3817.

https://doi.org/10.1182/blood-2008-05-157131

Published: 2008

Includes: Supplemental data

Journal Articles

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Saman Hewamana, Suhair Alghazal, Thet Thet Lin, Matthew Clement, Chris Jenkins, Monica L. Guzman, Craig T. Jordan, Sundar Neelakantan, Peter A. Crooks, Alan K. Burnett, Guy Pratt, Chris Fegan, Clare Rowntree, Paul Brennan, Chris Pepper

Blood (2008) 111 (9): 4681–4689.

https://doi.org/10.1182/blood-2007-11-125278

Published: 2008

Journal Articles

Transcription Factor NF-kB as a Biomarker for Disease Progression and Target for Treatment in Chronic Lymphocytic Leukaemia.

Saman Hewamana, MRCP, MRCPath, Mathew Clement, BSc, Thet Thet Lin, PhD, Chris Jenkins, MRCP, Chris Fegan, FRCP,FRCPath,MD, Clare Rowntree, FRCP,MRCPath,PhD, Paul Brennan, PhD, Chris Pepper, PhD

Blood (2007) 110 (11): 3091.

https://doi.org/10.1182/blood.V110.11.3091.3091

Published: 2007

Journal Articles

Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.

Saman Hewamana, MB, Clare Rowntree, MB, PhD, Thet Thet Lin, PhD, Chris Pepper, PhD, Paul Brennan, PhD, Chris Fegan, MD

Blood (2006) 108 (11): 4974.

https://doi.org/10.1182/blood.V108.11.4974.4974

Published: 2006

NARROW

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis

L-Gossypol Inhibits NF- κB, Down Regulates Mcl-1 and Induces Apoptosis of Primary Acute Myeloid Leukaemia Cells.

Rel a Is a Novel Prognostic Marker in CLL That Is Independent of V H Gene Mutation Status, CD38 Expression and ZAP-70 Expression

Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells

The Parthenolide Derivative LC-1 Is An Effective Single Agent and Is Highly Synergistic with Existing Therapies in Multiple Myeloma.

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Transcription Factor NF-kB as a Biomarker for Disease Progression and Target for Treatment in Chronic Lymphocytic Leukaemia.

Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only